EZH2 and cholangiocarcinoma: Paolicchi et al. studied 75 patients with advanced CCA and observed a trend for lower risk of death (HR = 0.59, 95% CI 0.33–1.05, p = 0.075) and for longer overall survival (p = 0.036) in EZH2 rs887569 TT genotype [99].